This activity is supported by an educational grant from Allergan, Inc.

Activity release date:  January 10, 2019    Activity expiration date:  January 10, 2020

Uterine fibroids (UFs) are one of the most common benign neoplasms of the female genitourinary tract, impacting as many as 80% of women by age 50. While minimally invasive, uterine and/or fertility-sparing management options are available, invasive surgical intervention continues to be the most commonly used management option for patients with UFs, even though it is often least preferred by patients. Practice observations and peer-reviewed literature indicate that a major contributor to the high rates of invasive treatment is a result of shortcomings in clinicians’ ability to present patients with all possible treatment options. Addressing these practice gaps is increasingly important in light of both the growing evidence supporting the efficacy and safety of minimally invasive treatment options and the potential availability of novel pharmacotherapy management strategies, which may offer longer-term medical management options. As a result, it is crucial that nurse practitioners (NPs) and clinicians, who are on the frontlines of women’s healthcare, are proficient not only in the effective recognition/diagnosis of patients with UFs and the appropriate use of currently available management strategies, but also in their understanding of emerging investigational agents and their potential implications on treatment paradigms and clinical practice.

The goal of this activity is to enhance the capabilities of NPs to participate in the comprehensive management of patients with UFs by presenting strategies to identify symptoms and diagnose UFs, evaluating the breadth of treatment options available for UFs, discussing the potential implications of novel medical management strategies, and reviewing NP-driven strategies to communicate with patients and establish and achieve shared treatment goals.

This educational activity is designed for nurse practitioners, as well as obstetricians, gynecologists, and other healthcare providers involved in the management of women’s health and uterine fibroids.

Upon completion of the educational activity, participants should be able to:
  • IDENTIFY risk factors for, and symptoms suggestive of, UF to improve diagnosis and treatment as part of comprehensive women’s healthcare.
  • COMPARE available options for managing UF to facilitate the appropriate use of minimally-invasive treatments.
  • IMPLEMENT strategies that assess individual patient goals and preferences, considering all UF treatment options, to inform decision-making.
  • ASSESS the potential clinical implications of novel pharmacotherapies as part of the comprehensive management of UFs.
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and ASiM CE, LLC.

AKH logoThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and ASiM CE, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME.

AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is awarded 1.25 Contact Hours

Nurse Practitioners
AANP logoThis activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and ASiM CE, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education.
Provider number: 030803

This activity is awarded 1.25 contact hours which includes 0 hours of pharmacology. Program ID #218168.

This activity was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.

In order to receive credit, participants should watch the entire video. Once you have watched the video, you will continue to the online quiz and evaluation. A passing score of 70% on the quiz is required to receive credit. A certificate will be available upon successful completion of the quiz and evaluation. If you have questions about this CME activity, please contact AKH Inc. at There is no fee for this activity.

This activity is supported by an educational grant from Allergan, Inc.

Heidi Collins Fantasia PhD, RN, WHNP-BC
Associate Professor
Zuckerberg College of Health Sciences
Solomont School of Nursing
University of Massachusetts Lowell
Lowell, MA
Heidi Collins Fantasia has disclosed no financial relationships.

Allyssa L. Harris, RN, PhD, WHNP-BC
Associate Professor
WHNP Program Director
William F. Connell School of Nursing
Boston College
Chestnut Hill, MA
Allyssa L. Harris has disclosed no financial relationships.

Dr. Sukhbir Sony Singh MD, FRCSC, FACOG
Associate Professor, University of Ottawa
E. Jolly Research Chair in Gynecologic Surgery
Division of General Obstetrics and Gynecology
Department of Obstetrics, Gynecology and Newborn Care
Ottawa, ON, Canada
Dr. Singh has disclosed the following relevant financial relationships:
Consultant: AbbVie, Allergan, Bayer
Contracted Research: AbbVie, Allergan, Bayer as a primary investigator through Ottawa Hospital Research Institute
Speakers Bureau: AbbVie, Allergan, Bayer

Staff and Planners
Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has disclosed no relevant financial relationships.
Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has disclosed no relevant financial relationships.
Patricia Brignoni, AKH Sr. Project Manager: has disclosed no relevant financial relationships.
Steve Eckert, AKH President & CEO, Planner: has disclosed no relevant financial relationships.
Jessica Marshall, PhD, Executive Medical Director: has disclosed no relevant financial relationships.

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

Required hardware/software:

  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.


Identifying Women with Uterine Fibroids:
The Importance of A Proactive Pro

Evaluating the Minimally Invasive Treatment Landscape for UF Management

Addressing Unmet Patients’ Needs With Novel Pharmacological UF Treatments

Presenting All the Options:
Improving the Appropriate Use of Minimally Invasive Treatments

Question and Answer Session

Postassessment and Evaluation

CONVERSATION GUIDE (click to download your copy)

Copyright 2018 ASiM CE, LLC. No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher.

Submit a case to review at meeting:

procced to pretest

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us